COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC:
Get the latest research information from NIH:

Coronavirus Guidance for NIH Applicants and Grantees:

Dr. Michael Eissenstat

Dr. Michael Eissenstat

Scientific Review Officer


Division of Basic and Integrative Biological Sciences DBIB
Biological Chemistry and Macromolecular Biophysics BCMB
Study Section:
Synthetic and Biological Chemistry B SBCB

Dr. Mike Eissenstat is the Scientific Review Officer for the Synthetic and Biological Chemistry B (SBCB) study section.

Until recently he ran the Fellowships: Synthetic and Biological Chemistry F04A-W(20) panel. He received his Ph.D. in organic chemistry from Harvard University and did postdoctoral work in organic synthesis at the University of Pittsburgh. He then joined Sterling Drug as a medicinal chemist, where he worked in many therapeutic areas and was co-project leader of the analgesics project team. He subsequently joined the Structural Biochemistry Program of SAIC at NCI-Frederick where he worked on structure based drug design of HIV protease and other aspartyl protease inhibitors. Then, after a brief stint at Tibotec Inc. as Associate Director, he helped found Sequoia Pharmaceuticals. As the Vice President of Chemistry at Sequoia his team discovered the HIV protease inhibitor SPI-256 and the PK enhancer SPI-452. Both of these compounds completed Phase 1 clinical trials. Dr. Eissenstat joined the Biological Chemistry and Macromolecular Biophysics (BCMB) Integrated review Group (IRG) at CSR in 2012.